Gloves come off as Moderna fights for pandemic revenues

26 August 2022
moderna_big

Threatening to upset Pfizer’s (NYSE: PFE) dominance of the multi-billion dollar coronavirus vaccine market, Moderna (Nasdaq: MRNA) is today starting legal action against the firm, claiming patent infringement.

The company has previously pledged not to enforce its patents while the pandemic continued, but as the acute phase of the health emergency recedes, Moderna is taking a more combative stance.

Since the start of the pandemic, Pfizer and co-developer BioNTech (Nasdaq: BNTX) - also a target in the litigation - have made tens of billions of dollars.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology